Announcements Trials
Browse Landscape

Phase

Phase 1/2 12Phase 1 5Phase 3 4Phase 2 3

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Non-Hodgkin 1Lymphoma 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × polatuzumab vedotin × Clear all
NCT03274492 2026-05-08

POLARIX

Hoffmann-La Roche

Phase 3 Completed
1,000 enrolled 1 FDA
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05171647 2026-05-07

SUNMO

Hoffmann-La Roche

Phase 3 Active not recruiting
208 enrolled 12 charts
Lymphoid

Lymphoma, Non-Hodgkin

NCT04182204 2025-12-22

POLARGO

Hoffmann-La Roche

Phase 3 Completed
270 enrolled 36 charts
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT04236141 2023-03-03

A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).

Hoffmann-La Roche

Phase 3 Terminated
42 enrolled 28 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡